Drug price setting is selfishly shortsighted

Prescription drug price-setting proposals keep coming up in Congress with the purported aim of lowering prescription drug prices and improving Medicare. In fact, the Biden administration’s Build Back Better Act (BBBA) contains such provisions, and some usually level-headed members of Congress have recently expressed openness to passing those drug price-setting provisions as a scaled-back, stand-alone bill. Yet all such proposals are selfishly shortsighted and ultimately lead to lower quality, fewer options, diminished health outcomes, and establish price controls that could exacerbate inflation or lead to shortages.

Read the full TAPP opinion column in The Hill here.